The Emerging Role of Selective S1P-Based Therapeutics in the Management of Patients With Multiple Sclerosis

Course Information

Therapautic Area: Neurology
Format(s): Webcast
Credit(s): 1.00 AMA PRA Category 1 Credit(s)™
Activity Dates: March 24, 2017 to March 23, 2018


Program Overview

This enduring CME webcast was derived from content presented at a live symposium at the ACTRIMS Forum 2017 held in Orlando, Florida. Five expert faculty will discuss sphingosine-1-phosphate science, and provide an update on selective S1P receptor modulators. Practical assessment of benefits versus risk, including infectious disease risk, in patients treated with S1P therapeutics, will be reviewed. Faculty will relay best practices for shared decision making through patient education as well as strategies for engagement of the multidisciplinary team. Upon completion of this educational activity, learners will gain better insight into the emerging role of S1P-based therapeutics in the management of patients with multiple sclerosis.

Target Audience

Neurologists, and other healthcare professionals who care for patients with MS.

Learning Objectives

  1. Understand the science of selective sphingosine-1-phosphate therapeutics.
  2. Analyze current and emerging clinical trial data for selective S1P-based therapeutics for the management of patients with MS.
  3. Evaluate the benefit vs. risk balance for pharmacotherapeutic options to treat patients with MS.



Lublin_Head Shot_ACTRIMSFred D. Lublin, MD (Chair)
Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, New York



Antel_Head Shot_ACTRIMSJack Antel, MD
Professor of Medicine
Montreal Neurological Institute and Hospital
McGill University
Montreal, Quebec, Canada



Berger_Head Shot_ACTRIMSJoseph R. Berger, MD
Professor of Neurology and MS Division Chief
Department of Neurology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania



Fredman_Head Shot_ACTRIMSMark S. Freedman, MD
Professor of Medicine
University of Ottawa
Senior Scientist
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada


Perrin Ross_HeadshotAmy Perrin Ross, APN, MSN, CNRN, MSCN
Neuroscience Program Coordinator
Loyola University Medical Center
Maywood, Illinois



Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


Faculty Relationship Identified With:
Fred D. Lublin, MD Consultant/Advisor: AbbVie Inc.; Actelion Pharmaceuticals; Acorda Therapeutics; Akros Pharma Inc.; Amgen Inc.; Atara Biotherapeutics; Bayer AG; Biogen; Celgene Corporation; EMD Serono, Inc.; Forward Pharma; Genentech, Inc.; Genzyme Corporation; Mapi-Pharma Ltd.; Medday; MedImmune; POLYPHARMA; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; Roche; Teva Pharmaceutical Industries Ltd.; TG Therapeutics, Inc.; ToyamaGrant/Research Support: Biogen; Celgene Corporation; Genzyme Corporation; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; Teva Pharmaceutical Industries Ltd.; Transparency Life Sciences

Speaker’s Bureau: Genentech, Inc.; Genzyme Corporation

 Jack Antel, MD Grant/Research Support: Novartis Pharmaceuticals Corporation
Joseph R. Berger, MD  Consultant/Advisor: Amgen Inc.; AstraZeneca; Bayer AG; Biogen; Eisai Co., Ltd.; Forward Pharma; Genentech, Inc.; Genzyme Corporation; Incyte Corporation; Inhibikase Therapeutics, Inc.; Janssen Global Services, LLC; Johnson & Johnson Services, Inc; Novartis Pharmaceuticals Corporation; PAREXEL International Corporation; Pfizer Inc.; Roche; Takeda Pharmaceuticals U.S.A., Inc.Grant/Research Support: Biogen; Teva Pharmaceutical Industries Ltd.
 Mark S. Freedman, MD   Consultant/Advisor: Actelion Pharmaceuticals; Bayer AG; Biogen; Chugai Pharmaceutical Co., Ltd.; EMD Serono, Inc.; Genzyme Corporation; MedDay; Merck & Co.; Novartis Pharmaceuticals Corporation; Roche; sanofi-aventis U.S. LLC; Teva Canada InnovationGrant/Research Support: Genzyme Corporation

Speaker’s Bureau: Genzyme Corporation

 Amy Perrin Ross, APN, MSN, CNRN, MSCN   Consultant/Advisor: Acorda Therapeutics; Bayer AG; Genentech, Inc.; Genzyme Corporation; Roche; Teva Pharmaceutical Industries Ltd.Speaker’s Bureau: Acorda Therapeutics; Biogen; EMD Serono, Inc.; Genzyme Corporation; Mallinckrodt Pharmaceuticals; Novartis Pharmaceuticals Corporation; Teva Pharmaceutical Industries Ltd.


Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Gilmartin and Nicole Brestowski hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Celgene Corporation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Celgene Corporation do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact

Provided by AcademicCME

AcademicCME Logo